239 related articles for article (PubMed ID: 28149332)
21. Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
Liu M; Thomas SL; DeWitt AK; Zhou W; Madaj ZB; Ohtani H; Baylin SB; Liang G; Jones PA
Cancer Res; 2018 Oct; 78(20):5754-5766. PubMed ID: 30185548
[TBL] [Abstract][Full Text] [Related]
22. Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001.
Cirrik S; Ugurel E; Aksu AC; Oronsky B; Cabrales P; Yalcin O
Biorheology; 2019; 56(4):221-235. PubMed ID: 31640080
[TBL] [Abstract][Full Text] [Related]
23. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Scicinski J; Fisher G; Carter C; Cho-Phan C; Kunz P; Ning S; Knox S; Oronsky B; Caroen S; Parker C; Fanger G; Reid T
Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162292
[TBL] [Abstract][Full Text] [Related]
24. Rockets, radiosensitizers, and RRx-001: an origin story part I.
Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
Discov Med; 2016 Mar; 21(115):173-80. PubMed ID: 27115167
[TBL] [Abstract][Full Text] [Related]
25. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.
Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G
Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533
[TBL] [Abstract][Full Text] [Related]
26. Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Oronsky B; Oronsky N; Knox S; Fanger G; Scicinski J
Anticancer Agents Med Chem; 2014; 14(8):1121-7. PubMed ID: 24893730
[TBL] [Abstract][Full Text] [Related]
27. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
28. Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.
Liu M; Ohtani H; Zhou W; Ørskov AD; Charlet J; Zhang YW; Shen H; Baylin SB; Liang G; Grønbæk K; Jones PA
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10238-44. PubMed ID: 27573823
[TBL] [Abstract][Full Text] [Related]
29. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.
Yalcin O; Oronsky B; Carvalho LJ; Kuypers FA; Scicinski J; Cabrales P
Malar J; 2015 May; 14():218. PubMed ID: 26017006
[TBL] [Abstract][Full Text] [Related]
30. Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE.
Perl A; Nagy G; Koncz A; Gergely P; Fernandez D; Doherty E; Telarico T; Bonilla E; Phillips PE
Autoimmunity; 2008 May; 41(4):287-97. PubMed ID: 18432409
[TBL] [Abstract][Full Text] [Related]
31. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.
Vitiello GAF; Ferreira WAS; Cordeiro de Lima VC; Medina TDS
Front Immunol; 2021; 12():782852. PubMed ID: 34925363
[TBL] [Abstract][Full Text] [Related]
32. Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Oronsky B; Reid T; Cabrales P
J Drug Target; 2021 Nov; 29(9):998-1003. PubMed ID: 34016002
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Chiappinelli KB; Strissel PL; Desrichard A; Li H; Henke C; Akman B; Hein A; Rote NS; Cope LM; Snyder A; Makarov V; Budhu S; Slamon DJ; Wolchok JD; Pardoll DM; Beckmann MW; Zahnow CA; Merghoub T; Chan TA; Baylin SB; Strick R
Cell; 2015 Aug; 162(5):974-86. PubMed ID: 26317466
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of novel 3-halo-3-nitroflavanones and their activities as DNA methyltransferase inhibitors in cancer cells.
Pechalrieu D; Dauzonne D; Arimondo PB; Lopez M
Eur J Med Chem; 2020 Jan; 186():111829. PubMed ID: 31757526
[TBL] [Abstract][Full Text] [Related]
35. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Reu FJ; Leaman DW; Maitra RR; Bae SI; Cherkassky L; Fox MW; Rempinski DR; Beaulieu N; MacLeod AR; Borden EC
Cancer Res; 2006 Mar; 66(5):2785-93. PubMed ID: 16510600
[TBL] [Abstract][Full Text] [Related]
36.
Magnani E; Macchi F; Madakashira BP; Zhang C; Alaydaroos F; Sadler KC
Front Immunol; 2021; 12():627926. PubMed ID: 33854502
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.
Daskalakis M; Brocks D; Sheng YH; Islam MS; Ressnerova A; Assenov Y; Milde T; Oehme I; Witt O; Goyal A; Kühn A; Hartmann M; Weichenhan D; Jung M; Plass C
Cell Cycle; 2018; 17(7):811-822. PubMed ID: 29633898
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
Scicinski J; Oronsky B; Taylor M; Luo G; Musick T; Marini J; Adams CM; Fitch WL
Drug Metab Dispos; 2012 Sep; 40(9):1810-6. PubMed ID: 22699395
[TBL] [Abstract][Full Text] [Related]
39. Development of methods for the bioanalysis of RRx-001 and metabolites.
Scicinski J; Oronsky B; Cooper V; Taylor M; Alexander M; Hadar R; Cosford R; Fleischmann T; Fitch WL
Bioanalysis; 2014 Apr; 6(7):947-56. PubMed ID: 24806903
[TBL] [Abstract][Full Text] [Related]
40. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff F; Leisch M; Greil R; Risch A; Pleyer L
Cell Commun Signal; 2017 Mar; 15(1):13. PubMed ID: 28359286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
